NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 182 filers reported holding NEVRO CORP in Q2 2022. The put-call ratio across all filers is 1.60 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,024,216 | -21.4% | 729,574 | +4.0% | 0.00% | 0.0% |
| Q2 2023 | $17,837,349 | -25.1% | 701,705 | +6.5% | 0.00% | -33.3% |
| Q1 2023 | $23,812,487 | +95771.2% | 658,713 | +5.0% | 0.00% | 0.0% |
| Q4 2022 | $24,838 | -99.9% | 627,238 | +3.6% | 0.00% | -25.0% |
| Q3 2022 | $28,211,000 | +8.9% | 605,391 | +2.4% | 0.00% | 0.0% |
| Q2 2022 | $25,902,000 | -40.3% | 590,974 | -1.5% | 0.00% | -20.0% |
| Q1 2022 | $43,409,000 | -6.4% | 600,154 | +4.9% | 0.01% | -16.7% |
| Q4 2021 | $46,368,000 | -29.1% | 571,954 | +1.8% | 0.01% | -33.3% |
| Q3 2021 | $65,394,000 | -32.3% | 561,901 | -3.6% | 0.01% | -30.8% |
| Q2 2021 | $96,588,000 | +24.0% | 582,596 | +4.4% | 0.01% | +8.3% |
| Q1 2021 | $77,866,000 | -12.4% | 558,186 | +8.7% | 0.01% | -20.0% |
| Q4 2020 | $88,888,000 | +31.6% | 513,511 | +5.9% | 0.02% | +15.4% |
| Q3 2020 | $67,532,000 | +14.2% | 484,797 | -2.1% | 0.01% | 0.0% |
| Q2 2020 | $59,137,000 | +34.0% | 495,002 | +12.2% | 0.01% | +18.2% |
| Q1 2020 | $44,122,000 | -53.7% | 441,319 | -45.6% | 0.01% | +10.0% |
| Q4 2019 | $95,378,000 | +192.7% | 811,464 | +114.1% | 0.01% | +25.0% |
| Q3 2019 | $32,588,000 | +36.3% | 379,068 | +2.8% | 0.01% | +33.3% |
| Q2 2019 | $23,906,000 | +12.3% | 368,760 | +8.3% | 0.01% | 0.0% |
| Q1 2019 | $21,281,000 | -11.4% | 340,454 | -44.9% | 0.01% | +50.0% |
| Q4 2018 | $24,032,000 | +49.2% | 617,990 | +118.6% | 0.00% | -20.0% |
| Q3 2018 | $16,110,000 | -23.7% | 282,639 | +6.9% | 0.01% | -16.7% |
| Q2 2018 | $21,115,000 | +0.9% | 264,437 | +9.5% | 0.01% | -14.3% |
| Q1 2018 | $20,924,000 | +28.5% | 241,422 | +2.3% | 0.01% | +16.7% |
| Q4 2017 | $16,285,000 | -23.6% | 235,883 | +0.6% | 0.01% | -25.0% |
| Q3 2017 | $21,307,000 | +53.2% | 234,455 | +25.5% | 0.01% | +60.0% |
| Q2 2017 | $13,905,000 | -15.6% | 186,822 | +6.3% | 0.01% | -28.6% |
| Q1 2017 | $16,469,000 | +37.9% | 175,766 | +6.9% | 0.01% | +16.7% |
| Q4 2016 | $11,942,000 | -24.6% | 164,362 | +8.3% | 0.01% | -25.0% |
| Q3 2016 | $15,837,000 | +107.3% | 151,711 | +46.5% | 0.01% | +100.0% |
| Q2 2016 | $7,638,000 | +51.4% | 103,562 | +15.5% | 0.00% | +33.3% |
| Q1 2016 | $5,044,000 | -14.9% | 89,667 | +2.2% | 0.00% | 0.0% |
| Q4 2015 | $5,924,000 | +53.7% | 87,760 | +5.6% | 0.00% | +50.0% |
| Q3 2015 | $3,854,000 | -11.7% | 83,099 | +2.3% | 0.00% | 0.0% |
| Q2 2015 | $4,366,000 | +100.8% | 81,228 | +79.1% | 0.00% | +100.0% |
| Q1 2015 | $2,174,000 | +220.6% | 45,363 | +158.4% | 0.00% | – |
| Q4 2014 | $678,000 | – | 17,552 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |